Zinzino Reports 15% Revenue Growth in August 2026, Driven by North America and Central Europe
Event summary
- Zinzino's group revenue increased by 15% year-over-year to SEK 282.2 million in August 2026.
- North America saw the highest growth at 61%, while Central Europe grew by 18%.
- Faun Pharma's external sales declined by 62% to SEK 1.3 million.
- Year-to-date revenue for January–August 2026 increased by 22% to SEK 2,464.8 million.
The big picture
Zinzino's strong August performance highlights its ability to capitalize on high-growth markets like North America and Central Europe. However, the decline in Faun Pharma's sales and weaker performance in Eastern Europe suggest potential challenges in maintaining balanced regional growth. The company's strategic focus on direct selling and nutritional supplements continues to drive revenue, but sustaining this momentum will require addressing regional disparities and stabilizing its pharmaceutical segment.
What we're watching
- Regional Strategy
- How Zinzino will sustain growth in North America and Central Europe amid declines in Eastern Europe and the Baltics.
- Pharma Segment
- Whether Faun Pharma can recover from its 62% sales decline and contribute meaningfully to group revenue.
- Market Expansion
- The pace at which Zinzino can expand in high-growth regions like South America, which saw a 323% year-to-date increase.
Related topics